Report: OTC Reforms Costly For Buy Side
Buy-side firms and other end users will face skyrocketing reporting and systems costs if they are caught up in over-the-counter derivatives regulation meant primarily for liquidity providers, according to a report from Aite Group.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
